Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Summary

The primary objective of the study is to characterize the pharmacokinetics (PK) of rFVIIIFc administered at vial strengths of 1000 and 3000 IU in subjects with severe hemophilia A. The secondary objective of the study is to evaluate the safety of rFVIIIFc beyond the PK assessment for up to 6 months for a continued treatment period.

Timeline

Start

2014-03

Primary completion

2014-10

Completion

2015-05

Drugs

Indications